ERBB2 and breast cancer: These findings are in contrast to the published analysis by Blum et al. from the ABC trials (n = 4242 patients), which could not demonstrate non-inferiority of anthracycline-free therapy (TC6) compared to anthracycline-containing regimens with regard to invasive DFS in patients with high-risk HER2-negative early breast cancer [9].